Delivery Order SPE2DB24D8002-SPE2DB25FJNKP
Award Date
3/28/25
Potential Completion Date
3/31/25
Potential Value
$9.6K
Federal Agency
Defense Logistics Agency
Awardee
Dakota Drug, Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Anoka, MN, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $13,666.77, is for the delivery of Dupixent 300 mg/2 ml syringes to support U.S. Armed Forces medical operations. The contract is a firm-fixed-price, unrestricted (no set-aside) contract with a performance period ending on April 29, 2024. Dakota Drug, Inc. is a key supplier of pharmaceutical products, medical...
This federal contract award to Dakota Drug, Inc., a self-certified small disadvantaged business, involves the delivery of Dupixent 300 mg/2 ml syringes to the Defense Logistics Agency (DLA) Troop Support Medical division. The contract has a firm fixed price of $2,345.09 and a period of performance through November 15, 2023. This award is part of Dakota Drug's larger Indefinite Delivery Contract (IDC) with the DLA, identified as SPE2DB24D8001, valued at $999,999,999.00, which allows the company...
The U.S. government's Defense Logistics Agency (DLA) awarded a $26,588.72 firm-fixed-price delivery order contract (SPE2DX15D8003|SPE2DX24F7D7B) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the supply of Dupixent 300 mg/2 ml syringes. The contract has a performance period through May 8, 2024. Dakota Drug, Inc. is a key supplier to the DLA Troop Support Medical division, holding a $999,999,999.00 Indefinite Delivery Contract (SPE2DB24D8001) as part of the DLA's ECAT...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the supply of the pharmaceutical product Dupixent 300 mg/2 ml syringe. The contract has a ceiling value of $7,469.04 and a period of performance ending on September 17, 2024. Dakota Drug, Inc. is a prime contractor to the DLA Troop Support Medical, playing a crucial role in supporting the medical supply chain operations for...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $23,237.03, is for the delivery of Dupixent 300 mg/2 ml syringes. Dakota Drug, Inc. is a key supplier of pharmaceutical products, medical supplies, and healthcare equipment to the U.S. federal government, particularly the Department of Defense. The company holds a significant single-award Indefinite Delivery...
The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract worth $7,091.73 to Dakota Drug, Inc., a self-certified small disadvantaged business located in Anoka, Minnesota. This contract, with a performance period ending on March 4, 2024, is for the delivery of Dupixent 300 mg/2 ml syringes. This award is part of a larger Indefinite Delivery Contract (IDC), identified as SPE2DB24D8001, which allows Dakota Drug, Inc. to provide a wide range of pharmaceutical...
This firm fixed-price delivery order was awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business operating as a for-profit subchapter S corporation. The $5,601.75 contract is for the supply of Dupixent 300 mg/2 ml syringes, with a performance period through August 1, 2024. Dakota Drug, Inc. holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical's ECAT Generation V Program, which allows...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $11,879.56, is for the delivery of Dupixent 300 mg/2 ml syringes to support U.S. Armed Forces medical operations. The contract has a firm fixed price pricing type and a performance period through January 23, 2024. Dakota Drug, Inc. holds a larger Indefinite Delivery Contract (IDC) with the DLA, valued at $999,999,999.00,...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the delivery of the pharmaceutical product Dupixent 300 mg/2 ml syringe. The contract has a ceiling value of $29,253.41 and a period of performance through September 19, 2024. Dakota Drug, Inc. is an experienced federal contractor, holding a $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical's ECAT...
This federal contract award, with ID SPE2DX15D8002|SPE2DX24F2WL7, was issued by the Defense Logistics Agency (DLA) to the prime contractor Dakota Drug, Inc., a self-certified small disadvantaged business. The $15,899.80 firm fixed-price delivery order is for the provision of the pharmaceutical product DUPIXENT 300 MG/2 ML SYRINGE 2ML, which supports medical supply chain operations for the U.S. Department of Defense. Dakota Drug, Inc. holds a significant single-award Indefinite Delivery...